Background: Idiopathic pulmonary arterial hypertension (IPAH) is a fatal disorder with a prevalence of 8.6 per million. We introduce a registry website for IPAH and PAH patients (www.IPAH.ir) for access and efficient delivery of government-aided and subsidized antihypertensive medications. Materials and Methods: The IPAH registry was opened in November 2009. Information of IPAH and PAH patients with a username and password were uploaded in the site. Data entry was possible only via the physicians and healthcare organizations via internet that were given a personalized username and password for entry. Following the patients' profile submission, a scientific committee composed of a cardiologist and a pulmonologist who were selected by the Ministry of Health of Iran (MOH), evaluated the data. The eligibility of the patient to receive the medications was confirmed after evaluation. If the patient was eligible, 82% of the Bosentan cost was paid by MOH. Results: To date, one hundred and sixteen patients (82 females, 34 males) have been registered. The mean pulmonary artery pressure by right heart catheterization was 69.24±17 mmHg (ranging from 35 to 110 mmHg).
INTRODUCTION
Pulmonary hypertension has been defined as an increase in the mean pulmonary arterial pressure (PAP) ≥ 25 mmHg at rest as assessed by right heart catheterization (1, 2) . This value has been used for selecting patients in all randomized clinical trials and registries of pulmonary arterial hypertension (3, 4) .
Pulmonary artery hypertension (PAH) is a fatal disease
with a prevalence of 15.5 per million. The prevalence of PAH is about 8.6 per million. The incidence of PAH is 1.2 per million (5) . According to the above-mentioned data, the number of cases with this disorder in Iran is estimated to be more than 137.
Pulmonary artery hypertension was a disease with low survival before the new generation of drugs; the mean survival in the afflicted subjects was 2.8 years, with one and three-year survival rates of 68% and 48%, respectively (1) . Substantial improvements obtained in survival rates in the past 20 years since institution of the NIH registry, due mainly to changes in treatment, improved patient support plans (6) . antagonists (7). These drugs have provided a new horizon in PAH remedy. Since the introduction of intravenous epoprostenol in 1995, the one and three-year survival rates have increased to 88% and 68%, respectively (8) .
Although the new marketed class of medications in the treatment of PAH over the past years, i.e. endothelin receptor antagonists, have significantly improved patient survival, these drugs are not affordable by most patients.
The cost of therapy with newer medications for PAH is up to 100,000$ per year (Table 1 )(9).
Bosentan, an endothelin receptor antagonist, costs about 44,878 USD per year for a PAH patient in Iran. Due to the duration of the disease and its high cost, the role of supportive organizations, insurance companies and charities in this regard is very important.
Considering the aforementioned facts, it would be justifiable to present a national data registry system for PAH to prevent inappropriate prescribing in order to ensure that the best possible care is delivered to those with this disease. It is worthy to note that the global trend is now moving towards a system of nominated centers for PAH care, with multidisciplinary teams working in a shared-care approach to patient supervision. The validated information and diagnoses were needed by the MOH to subsidize the cost for the patient.
We assess a registry site as a database for IPAH and PAH patients, for a better delivery of subsidized antihypertensive medications and to evaluate prognosis and survival in the future. Currently, the only medication for which the registry is used is Bosentan.
MATERIALS AND METHODS
The All patients included in our registry had a diagnosis of IPAH but it should be mentioned that in the vast majority of other PAH reports, secondary pulmonary hypertension cases were also included. We are to start registry on patients with PH secondary to diseases such as Eisenmenger and connective tissue disorders. Presenting a model like PAH registry in a national frame seems effective. Benefits of this model could be:
Increment of physician knowledge for standard diagnosis, prompt diagnosis, supporting drug supply for the patient and registration of data in a database. This is of great importance for the health budget by avoiding unnecessary and inappropriate resource consumption. Also, mentioned protocols for PAH patients enable physicians to provide the best available treatment regimens.
In conclusion, the Iranian registry for PAH patients has just started and it is believed that nationwide registry of these patients supplies essential information for health care providers in the field through a web-based program.
